Author

F. Alem

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:benchmarking· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. Narayanan· 3 shared A. Andalibi· 1 shared A. Bakovic· 1 shared A. Luchini· 1 shared A. Pak· 1 shared B. Hetrick· 1 shared D. Dabbagh· 1 shared E. Oktay· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Narayanan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

DNA Origami Presenting the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Response

E. Oktay, F. Alem, K. Hernandez, A. Narayanan, R. Veneziano

This study shows that DNA origami nanoparticles displaying SARS-CoV-2 RBD trimers and CpG adjuvants induce strong protective immunity in mice.

bioRxiv · Aug 2, 2022 · PreprintBioengineering

Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugs

B. Hetrick, S. He, L. D. Chilin, D. Dabbagh, F. Alem, A. Narayanan, A. Luchini, T. Li, X. Liu, J. Copeland, A. Pak, T. Cunningham, L. Liotta, E. Petricoin, A. Andalibi, Y. Wu

This paper develops a hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening of neutralizing antibodies, viral variants, and antiviral drugs, showing increased infectivity of variants and enhanced neutralization by post-vaccination serum.

bioRxiv · Dec 22, 2020 · PreprintMicrobiology

Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2

A. Bakovic, K. Risner, N. Bhalla, F. Alem, T. L. Chang, W. Weston, J. A. Harness, A. Narayanan

This paper shows brilacidin, a synthetic small molecule, strongly inhibits SARS-CoV-2 in cell cultures and works well with remdesivir.

bioRxiv · Oct 29, 2020 · PreprintMicrobiology